Astellas Pharma

Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha). On February 5, 2020, the company announced management changes effective from April 1, 2020.

"Astellas" redirects here. For similar sounding terms, see Astelia, Astellia, Astell, Astelma, and Astala.
Astellas Pharma Inc.
Company typePublic (K.K)
Traded as
  • TYO: 4503
  • TOPIX Core 30 Component
  • TOPIX 100 Component
  • Nikkei 225 Component
IndustryPharmaceutical
PredecessorsYamanouchi Pharmaceutical
Fujisawa Pharmaceutical
(Merged in 2005)
Founded1 April 2005 (2005-04-01)
Headquarters2-5-1, Nihonbashi-Honcho, Chūō-ku, Tokyo 103-8411, Japan
Key people
Naoki Okamura
(President and CEO)
Kenji Yasukawa
(Chairman of the Board)
Products
  • Prograf
  • Harnal
  • Vesicare
  • Funguard/Mycamine
  • Protopic
  • Xtandi
  • and other pharmaceuticals
Revenue US$11,060,000,000 (FY 2013)
Net income
 US$1,280,000,000 (¥1,139,000,000,000) (FY 2013)
Total assets$14.86 billion (2016)
Number of employees
17,217 (2016)
SubsidiariesAstellas US
Websitewww.astellas.com/en/
Footnotes / references

Astellas is a member of the Mitsubishi UFJ Financial Group (MUFJ) keiretsu.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.